Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Clinical Infectious DiseasesOpen Access

Cost-effectiveness of Targeted Next Generation Sequencing for TB drug-resistance testing as an alternative to the standard of care in South Africa

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAlexandra de NooySOShaheed Vally OmarTOTom Ockhuisen

Discussion

Loading...

Member takes

Overview

Analysis evaluates cost-effectiveness of tNGS versus standard of care for TB drug resistance, suggesting improved outcomes.

Key Points

  • tNGS averted 408 disability-adjusted life years, identifying 90.7% of resistance profiles compared to 87.7% with standard care.
  • Centralized tNGS was cost-saving; however, decentralization led to higher costs per DALY averted, ranging from $671 to $2,454.
  • Sensitivity analyses indicated that increased TB drug resistance and tNGS sensitivity improved cost-effectiveness outcomes.
  • Enhanced DST access via tNGS could amplify cost-effectiveness and patient outcomes in decentralized settings.

Cite This Study

Nooy et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478bee9https://doi.org/10.1093/cid/ciaf495
View Full Paper
Ask AI
Bookmark
Share